Prostamax is a prostate-derived bioregulatory peptide that has been investigated in experimental models of chronic aseptic prostate inflammation. Research data indicate that Prostamax is associated with a reduction in inflammatory markers, modulation of tissue remodeling processes, and prevention of fibrotic and atrophic changes within prostate tissue in animal-based studies. Additionally, experimental observations suggest an influence on functional activity parameters in studied models. Comparative research has shown that Prostamax demonstrates a broader and more sustained biological activity in prostate-focused experimental systems when compared with other commonly used prostatotropic research compounds of peptide origin.

Bremelanotide, also known as PT-141, is a synthetic peptide structurally related to alpha-MSH and melanocortin signaling molecules. It acts as an agonist of the MC3R and MC4R melanocortin receptors, which are involved in central nervous system pathways regulating motivation and arousal. By activating these receptors, PT-141 stimulates hypothalamic and related brain regions associated with sexual interest and behavioral response. Research indicates that its activity is centrally mediated rather than dependent on peripheral vascular mechanisms. While initially explored for sexual function in both men and women, scientific studies have shown particular relevance in premenopausal women experiencing conditions related to reduced sexual desire or arousal. According to research observations, PT-141 (Bremelanotide) has been associated with: Increased sexual desire and libido Higher frequency of sexual activity Support of erectile response in men with erectile dysfunction or impotence Potential benefit in premenopausal women with hypoactive sexual desire disorder Support in female sexual arousal–related dysfunctions Increased subjective energy and vitality levels

QK is a synthetic peptide designed to mimic the activity of Vascular Endothelial Growth Factor (VEGF), one of the primary regulators of angiogenesis (the formation of new blood vessels). Unlike full-length VEGF, QK is a smaller and more stable molecule that retains the ability to bind endothelial receptors (particularly VEGFR-1), activating key biological pathways involved in vascular growth. Its primary effect is the stimulation of angiogenesis, through: endothelial cell proliferation and migration formation of new capillary structures improvement of microcirculation These properties make QK highly relevant in research related to: tissue regeneration wound healing ischemic conditions (reduced blood flow) endothelial function and vascular health In summary, QK is a targeted angiogenic mimetic, useful for studying controlled vascular growth in experimental settings, offering improved stability and control compared to natural VEGF.

TELOMERE / IMMUNE MODULATION   Epitalon - 100mg + Thymalin - 100mg. Epitalon + Thymalin (Telomere / Immune Modulation) is a research peptide combination studied for its potential role in cellular aging pathways and immune system regulation. Epitalon has been widely investigated in relation to telomere biology, circadian rhythm signaling, and cellular homeostasis, while Thymalin has been explored for its involvement in immune modulation, thymic activity, and inflammation-related mechanisms. Together, this blend is primarily researched for its potential relevance in longevity-related cellular processes and support of immune function during aging.

TELOMERE / SENESCENT CELL TARGETING Epitalon - 100mg + FOX04 - DRI - 30mg  Epitalon + FOXO4-DRI is a research combination designed to explore two major biological pathways strongly associated with aging and cellular decline: telomere maintenance mechanisms and senescent cell signaling. Epitalon is widely studied for its potential involvement in telomerase-related pathways and circadian regulation, while FOXO4-DRI is a peptide of interest in senescence research due to its reported ability to interfere with FOXO4–p53 interactions in experimental models. This interaction has been associated with selective signaling effects in senescent cells, making FOXO4-DRI a key compound in research focused on senescent cell targeting and tissue homeostasis. Together, this combination is positioned for advanced research into mechanisms linked to cellular aging, tissue regeneration pathways, and biological resilience. According to experimental and preclinical research, this research set has been associated with the following areas of interest: Telomere biology and telomerase pathway research Senescent cell targeting and apoptosis-related signaling mechanisms Support of tissue homeostasis in aging models Investigation of cellular stress-response pathways Research into age-related functional decline at tissue and organ level Scientific interest in pathways related to immune regulation and systemic aging mechanisms All information provided above refers exclusively to laboratory, experimental, or preclinical research contexts and is intended for scientific and educational discussion only.

Reta is a next-generation metabolic research peptide classified as a multi-receptor agonist designed to interact with GLP-related, GIP-associated, and glucagon-mediated signaling pathways. By targeting multiple receptor systems simultaneously, it has become a key subject of investigation in studies focused on integrative metabolic regulation, energy balance, and complex signaling networks. Its molecular structure has been engineered to enhance stability and albumin binding, supporting an extended activity profile and improved pharmacokinetic characteristics in research environments. Current research explores its role in multi-pathway signaling dynamics, systemic regulatory processes, and advanced metabolic communication mechanisms.

Research suggests that Retinalamin is of interest in ophthalmology and retinal-support research due to its potential role in supporting retinal tissue function, microcirculation, and recovery mechanisms under conditions of degeneration or vascular stress. Studies indicate that it may be relevant in a range of retinal and vision-related disorders, including diabetic retinopathy, myopic disease, retinitis pigmentosa, age-related macular degeneration (AMD), chorioretinitis, primary open-angle glaucoma, and other eye diseases associated with impaired retinal performance and progressive vision decline.

RTD-1 is a macrocyclic θ-defensin peptide expressed in Old World monkeys and studied for its broad-spectrum antibacterial, antifungal, and antiviral activity. Research indicates it may function by interacting with microbial membranes while also exerting significant immunomodulatory effects. Notably, experimental studies in a rodent model of rheumatoid arthritis showed that RTD-1 rapidly suppressed and reversed autoimmune joint disease, improving mobility and preserving joint structure. Mechanistically, RTD-1 reduced joint IL-1β levels, inhibited IL-6 production, suppressed fibroblast-like synoviocyte invasiveness, and inhibited destructive proteases such as ADAM17/ADAM10, metalloproteases, and cathepsin K. These properties have positioned RTD-1 as a promising research peptide of interest in antimicrobial defense and inflammation-related disease models.

SEMA is a synthetic metabolic research peptide belonging to a class of regulatory compounds associated with incretin-related signaling pathways. It is widely studied for its interaction with receptor-mediated mechanisms involved in glucose handling, energy balance, and systemic metabolic regulation. Research interest also extends to its role in broader signaling networks, including those associated with cardiovascular function and neuroendocrine communication, making it a key compound in modern metabolic research models.

Sermorelin is a synthetic peptide derived from Growth Hormone-Releasing Hormone (GHRH) that stimulates the pituitary gland to increase endogenous growth hormone secretion. By activating GHRH receptors, Sermorelin promotes physiological GH release and enhances downstream IGF-1 production, supporting anabolic and regenerative signaling. Research suggests it may be relevant in studies involving body composition improvement, bone density support, metabolic regulation, and tissue repair. Additional research interest includes potential cardiovascular recovery effects through reduced scar remodeling, neuroprotective support via IGF-1-mediated neuronal resilience, and systemic benefits in chronic inflammation-related conditions. Due to its feedback-regulated mechanism and sustained receptor responsiveness, Sermorelin remains an important peptide in research related to endocrine aging, regeneration, and long-term metabolic health.

Setmelanotide is a synthetic peptide and potent melanocortin 4 receptor (MC4R) agonist studied for its ability to restore satiety signaling in rare genetic disorders such as POMC deficiency, PCSK1 deficiency, and leptin-related pathway dysfunction. It works by directly activating MC4R, bypassing upstream genetic defects that impair production of α-MSH and other satiety mediators. Research suggests that setmelanotide has significantly higher potency than endogenous α-MSH and may reduce hyperphagia and support weight loss in genetically defined obesity conditions. Its activity may be influenced by its atypical bitopic binding behavior, interacting with both orthosteric and putative allosteric receptor sites, potentially contributing to improved receptor specificity and a distinct signaling profile compared to earlier MC4R agonists.

SS-31 (Elamipretide) is a mitochondria-targeting peptide studied for its ability to bind cardiolipin in the inner mitochondrial membrane, stabilize mitochondrial structure, and support cellular energy production. Research suggests that SS-31 may reduce mitochondrial oxidative stress by limiting reactive oxygen species accumulation, improving mitochondrial bioenergetics, and supporting membrane integrity. It has also been investigated for its ability to modulate the mitochondrial permeability transition pore (mPTP), potentially reducing apoptosis-related signaling under stress. Due to these mechanisms, SS-31 has attracted attention in research involving neurodegenerative diseases, cardiovascular disorders, age-related mitochondrial decline, and retinal diseases such as diabetic retinopathy and age-related macular degeneration.

Taltirelin is a synthetic TRH analogue studied primarily for its effects in spinocerebellar degeneration and related motor coordination disorders. Acting as a biased superagonist at TRH-R1, it influences central neurotransmission and has been investigated for neuroprotective, anti-ataxic, and pro-cognitive effects. Research suggests taltirelin may modulate multiple neurotransmitter systems, including acetylcholine, dopamine, serotonin, and noradrenaline, contributing to interest in its potential relevance for memory impairment, depressive-like conditions, arousal regulation, and fatigue-related disorders. Additional studies have explored its antinociceptive properties and possible effects on neurite outgrowth and spinal cord-related neural recovery, making it a notable peptide in experimental research involving neurodegeneration, cognition, and neurological resilience.

Tesamorelin is a synthetic Growth Hormone-Releasing Hormone (GHRH) analogue designed for improved stability and extended activity in human plasma. By activating pituitary GHRH receptors, it stimulates endogenous growth hormone release while maintaining physiological pulsatile secretion patterns. This leads to increased downstream IGF-1 production, supporting anabolic and metabolic regulation. Research suggests tesamorelin may reduce visceral adipose tissue, support lean muscle maintenance, and influence metabolic health. It has been extensively studied in HIV-associated lipodystrophy, where reductions in abdominal fat have been associated with improved body composition markers and potential improvements in lipid-related cardiovascular risk factors. Emerging research also suggests possible relevance in cognitive aging and neuroendocrine function, as GH and IGF-1 pathways contribute to synaptic plasticity and brain metabolism.

Testagen is a bioregulatory peptide studied for its potential influence on endocrine balance, particularly in relation to thyroid hormone regulation and testosterone-related signaling. It has been described as a peptide capable of penetrating cellular structures and potentially influencing gene regulatory pathways. Research discussions suggest Testagen may support pituitary activity, increasing thyroid-stimulating hormone (TSH) output and indirectly supporting thyroid hormones T3 and T4, contributing to improved metabolism and energy regulation. It has also been explored for potential relevance in testosterone decline research, age-related vitality reduction, and hormonal imbalance-related conditions. Additional research interest includes its possible influence on hemostasis through thyroid-driven pathways and its potential immune-support relevance by modulating cellular differentiation and immune aging mechanisms.

Thymalin is a synthetic peptide bioregulator related to thymic factors such as thymulin, which are involved in immune signaling and the regulation of inflammatory pathways. Research has investigated Thymalin for its potential role in supporting immune function, modulating systemic homeostasis, and influencing age-associated immune decline. Studies suggest that Thymalin may contribute to improved immune resilience, cardiovascular function, and regulation of neuroendocrine processes linked to circadian rhythm and the sleep–wake cycle. It has also attracted significant interest in longevity research, as experimental findings have associated thymic peptide bioregulators with reduced mortality and lifespan extension in animal models.

Thymosin alpha-1 is a thymus-derived peptide widely studied as a potent regulator of immune function. It supports adaptive immunity by promoting T-cell maturation and enhancing immune communication through cytokine signaling pathways. Research in thymus-deficient models suggests thymosin alpha-1 may restore immune competence and improve resistance to infection. It has also been investigated as a vaccine adjuvant, potentially strengthening immune memory and improving the effectiveness of inactivated vaccines. In addition, thymosin alpha-1 has been studied in sepsis-related research due to its ability to modulate immune responses and potentially improve outcomes in severe infection-driven inflammatory states. These properties make thymosin alpha-1 a peptide of significant interest in research involving immune aging, infection susceptibility, vaccine response, and immune system resilience.

Thymosin Beta-4 (Tβ4), often associated with the peptide fragment TB-500 in research contexts, is a naturally occurring peptide involved in tissue repair, immune regulation, and cellular regeneration. Its primary mechanism is linked to actin-binding activity, supporting cytoskeletal remodeling and promoting cell migration essential for wound healing. Research suggests Tβ4 may stimulate angiogenesis, enhance collagen deposition, support keratinocyte and endothelial migration, and reduce inflammatory cytokine signaling through modulation of pathways such as NF-κB. It has been studied in experimental models of skin repair, corneal injury, dry eye conditions, cardiovascular remodeling after ischemic injury, systemic inflammation including sepsis models, neurological injury, autoimmune neuroinflammation, and musculoskeletal recovery. These properties make Tβ4 a major peptide of interest in regenerative biology and inflammation-related research.

Thyroidget (Asp–Trp) is a short bioregulatory peptide studied for its potential antioxidant and anti-inflammatory properties. Research suggests it may support cellular protection against oxidative stress and modulate inflammatory signaling pathways, making it relevant in studies involving chronic inflammatory disorders, cardiovascular risk models, and systemic aging processes. Due to the thyroid gland’s high metabolic activity and vulnerability to oxidative injury, Thyroidget has attracted interest as a peptide potentially supporting thyroid homeostasis and endocrine resilience, including research contexts related to autoimmune thyroid conditions. Emerging investigations also suggest possible neuroprotective relevance in models of neurodegenerative disease. Thyroidget is considered moderately water-soluble, with solubility influenced by pH, concentration, and ionic conditions.

Tirz is a synthetic dual-receptor metabolic research peptide designed to interact with GIP-associated and GLP-related signaling pathways. By targeting multiple incretin-associated receptor systems simultaneously, it has become a key subject of investigation in studies focused on metabolic regulation, energy balance, and coordinated signaling networks. Its multi-pathway activity supports research into integrative metabolic processes, cellular signaling dynamics, and system-wide regulatory mechanisms involved in nutrient-response and energy homeostasis.

TP508 is a 23–amino acid investigational regenerative peptide derived from amino acids 508–530 of human prothrombin. It has been studied for its ability to stimulate tissue repair by reversing endothelial dysfunction, promoting angiogenesis and revascularization, attenuating inflammation, and reducing apoptosis. Human studies have reported improved healing of diabetic foot ulcers and distal radius fractures, while animal studies suggest TP508 may stimulate bone regeneration in critical-size defects. Emerging evidence indicates that TP508 may activate tissue-derived stem/progenitor cells, which may contribute to its broad regenerative effects. Additional research has explored TP508 in cardiovascular ischemia models, where it increased perfusion and restored nitric oxide signaling through eNOS activation. TP508 has also been investigated as a potential countermeasure for radiation-induced gastrointestinal injury due to its potential role in supporting intestinal stem cell regeneration.

Thyrotropin-Releasing Hormone (TRH) is a naturally occurring tripeptide neurohormone best known for stimulating pituitary release of TSH and regulating thyroid hormone production. Beyond its classical endocrine role, TRH is widely distributed throughout the CNS and peripheral tissues, suggesting broader biological functions. Research indicates that TRH may influence immune development and immune homeostasis through interactions with cytokine signaling pathways, supporting its relevance in inflammatory disorders and cytokine-induced sickness behavior models. Animal studies have suggested that TRH may improve aging-related metabolic and hormonal parameters, including support for reproductive function, reduction of age-associated kidney degeneration, and modulation of fat metabolism. Additional investigations have explored TRH’s potential role in thymus-related immune resilience and pancreatic metabolic regulation.

Vesugen is a short synthetic bioregulatory peptide investigated for its role in vascular and neurovascular regulation. It belongs to a class of organ-specific peptides studied for their potential capacity to modulate gene expression patterns associated with endothelial stability, metabolic regulation, and cellular stress resistance. Experimental models have explored its interaction with genes such as p16 and p21 (cell cycle regulation), as well as pathways linked to SIRT1 activity, which is widely associated with metabolic control, stress adaptation, and longevity-related signaling mechanisms. Within neurovascular research contexts, Vesugen has been examined for its potential role in maintaining microvascular integrity and supporting oxidative balance in neural tissues. Additional research has evaluated Vesugen in the context of endothelial gene expression, nitric oxide signaling balance, and vascular membrane stability. Modulation of endothelin-1 expression and reduction of oxidative vascular markers have been reported in controlled laboratory studies. Overall, Vesugen is characterized in scientific literature as a vascular bioregulatory peptide investigated for its potential epigenetic modulation of gene expression related to endothelial function, neurovascular stability, metabolic balance, and cellular aging pathways.

Vilon is a thymus-derived bioregulatory peptide commonly described as the dipeptide Lys–Glu (KE). It is studied for its potential immune-modulating effects, particularly in the context of thymus-related immune function and T-cell regulation. Research suggests Vilon may support immune cell differentiation, normalize cytokine signaling, and contribute to immune homeostasis. These properties make it relevant in studies involving immunosenescence, age-related immune decline, chronic inflammation, infection susceptibility, and immune dysfunction. By supporting balanced immune regulation rather than excessive stimulation, Vilon has become a peptide of interest in research focused on immune resilience, systemic vitality, and longevity-related immune restoration.

VIP (Vasoactive Intestinal Peptide) is a 28–amino acid neuropeptide of the secretin–glucagon family, widely expressed in the brain, gastrointestinal tract, pancreas, lungs, heart, thyroid, adrenal glands, and thymus. It acts through the GPCR receptors VPAC1 and VPAC2, activating cAMP-related signaling pathways that regulate vascular tone, immune balance, secretion mechanisms, and neuronal survival. Research suggests VIP has neuroprotective and neurotrophic properties, supporting blood–brain barrier integrity, reducing oxidative stress, and modulating neuroinflammation, with relevance in neurodegenerative models such as Alzheimer’s and Parkinson’s disease. VIP also regulates circadian rhythm via hypothalamic signaling, supports gastrointestinal motility and barrier integrity, and has immunomodulatory effects by reducing pro-inflammatory cytokines and promoting immune tolerance. Additional studies indicate antifibrotic and vasodilatory activity relevant to cardiovascular and pulmonary disease models, as well as potential relevance in transplantation tolerance research and lacrimal secretion regulation in dry eye-related conditions.

α-Klotho is a transmembrane and soluble endocrine protein first identified in 1997 and now widely recognized as a key candidate in aging biology. It is expressed predominantly in the kidney and choroid plexus of the brain, and its soluble form circulates in blood, urine, and cerebrospinal fluid. Membrane α-Klotho functions as an essential co-receptor for FGF23, regulating phosphate and vitamin D metabolism. Soluble α-Klotho is studied for its broader endocrine-like effects, including modulation of oxidative stress responses, inflammatory signaling, IGF-1 and mTOR pathways, and Wnt-associated tissue remodeling. Experimental models show that Klotho deficiency is linked to accelerated aging-like phenotypes such as vascular dysfunction, sarcopenia, cognitive decline, cardiac fibrosis, and osteopenia, while elevated Klotho expression is associated with improved cognition, delayed vascular aging, enhanced muscle regeneration, and increased lifespan. Due to its connection with senescence biology, SASP-driven inflammation, kidney decline, and neurodegenerative processes, α-Klotho remains a central molecule in research focused on longevity, metabolic regulation, and systemic resilience.